---
layout: default
title: Pegfilgrastim
parent: Model Prediction Only (L5)
nav_order: 647
evidence_level: L5
indication_count: 2
---

# Pegfilgrastim
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **2** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Pegfilgrastim: From G-CSF-Based Neutrophil Support to Severe Nonproliferative Diabetic Retinopathy

## One-Sentence Summary

Pegfilgrastim is a PEGylated granulocyte-colony stimulating factor (G-CSF) analog; the specific original indication and mechanism-of-action text for this candidate were not provided in the current evidence pack (Data Gap DG002). The TxGNN model predicts potential relevance to **severe nonproliferative diabetic retinopathy**, but this prediction is supported by **0 clinical trials** and **0 publications** — it rests entirely on knowledge-graph topology, and the model's own mechanistic rationale flags a plausible risk of harm rather than benefit.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available — `original_indications` and `original_moa` are empty/gapped in this evidence pack (Data Gap DG002) |
| Predicted New Indication | Severe nonproliferative diabetic retinopathy |
| TxGNN Prediction Score | 99.89% (rank 2523) |
| Evidence Level | L5 (model prediction only, no clinical or literature support) |
| India Market Status | Not marketed (Not marketed) |
| Number of Registrations | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for this drug is not available in the evidence pack (Data Gap DG002). Based on general pharmacological knowledge, Pegfilgrastim belongs to the G-CSF analog class, whose established biological activity is stimulating proliferation and differentiation of granulocyte precursors — a mechanism with no established connection to retinal vascular biology.

The evidence pack's own mechanistic rationale is notably cautionary rather than supportive: it notes that G-CSF analogs lack any known anti-angiogenic or retinoprotective mechanism, and that their known properties — mobilizing hematopoietic/progenitor cells, pro-inflammatory signaling, and potential pro-angiogenic activity — could theoretically be **harmful rather than beneficial** in diabetic retinopathy, particularly in the severe nonproliferative stage where progression to proliferative (neovascular) disease is a key risk. The same caution applies to the second-ranked candidate, plain diabetic retinopathy (score 99.73%, rank 5308), where the source evidence explicitly flags a hypothetical risk of aggravating pathological neovascularization.

In short, the high TxGNN score (99.89%) reflects a graph-topology association only (likely via shared inflammation/angiogenesis-related nodes) and should **not** be read as mechanistic support for efficacy. Both candidate indications carry `decision_stage: S0` and `recommendation: Hold` in the source scoring, consistent with this being an exploratory signal rather than a validated hypothesis.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## India Market Information

Pegfilgrastim is currently not marketed in India under this evidence pack (`market_status: Not marketed`, 0 registrations); no license records are available to summarize.

---

## Safety Considerations

**Key warnings and contraindications** are not available in this evidence pack (Data Gap DG001, classified as *Blocking* — this gap alone prevents the candidate from clearing the S1 safety pre-screen).

**Drug Interactions**: A DDI query returned 147 total interactions (source: ddinter), predominantly rated Moderate. Notable patterns among the interacting agents:
- **Radiopharmaceutical/imaging agents**: Iobenguane (I-131), Fludeoxyglucose (18F), Ibritumomab tiuxetan, Tositumomab / Tositumomab (I-131) — G-CSF-stimulated marrow activity can interfere with these agents' distribution or imaging/therapeutic accuracy.
- **Cytotoxic/myelosuppressive chemotherapy agents**: Mercaptopurine, Paclitaxel, Trimetrexate, Altretamine, Arsenic trioxide, Azacitidine, Asparaginase (E. coli) — concurrent use requires attention to timing relative to chemotherapy cycles, per standard G-CSF class labeling practice.
- **Immunomodulators/targeted agents**: Pegvaliase, Alemtuzumab, Aldesleukin, Acalabrutinib, Abemaciclib, Avapritinib, Belantamab mafodotin, Levamisole — several carry their own myelosuppression or immune-related risk profiles.

This list represents the 20 highest-priority entries out of 147 total; full interaction detail should be reviewed before clinical use.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The candidate has no clinical trial or literature evidence (L5, prediction-only), and the source data's own mechanistic rationale suggests the G-CSF pathway may plausibly worsen rather than treat diabetic retinopathy. Combined with a Blocking data gap on TFDA-equivalent label warnings/contraindications (DG001), this candidate does not meet the bar to proceed.

**To proceed, the following is needed:**
- TFDA/regulatory label warnings and contraindications (resolves DG001, Blocking)
- Confirmed original indication and mechanism-of-action data (resolves DG002, High)
- Preclinical or mechanistic studies specifically evaluating G-CSF pathway effects on retinal vasculature, given the theoretical concern for pro-angiogenic harm
- Any real-world or case-level evidence of G-CSF exposure in diabetic retinopathy patients, to assess whether the graph-predicted association reflects a genuine signal or confounding
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

